Penny Stocks To Watch After The Holidays
Investors are finding penny stocks to watch as markets heat up into the end of 2020. With the pandemic in mind and a new president on the horizon, 2021 could have a lot of potential for different sectors and industries. But, investors should still make sure to do all of the research they can.
When searching for hot penny stocks, the best place to start is by finding an industry of interest (and one that’s trending doesn’t hurt either). For this, we have to consider current events and what could happen to the industry in the future. For example, with the election of Joe Biden, many investors are turning to renewable energy stocks and electric vehicle penny stocks. This is due to Biden’s plan of making the U.S. fossil fuel-free within the next few decades.
In addition, the pandemic has led to heightened interest in biotech and biopharmaceutical stocks. Another factor to keep in mind is that penny stocks are notoriously volatile and speculative. This comes in handy, particularly with short-term traders. But, this means that investors still need to pay attention to the news and what is occurring in each specific industry of interest. With all of this in mind, let’s take a closer look at three hot penny stocks to watch right now.
How Penny Stocks to Watch
- MannKind Corp. (MNKD Stock Report)
- Opko Health Inc. (OPK Stock Report)
- Northwest Biotherapeutics Inc. (NWBO Stock Report)
Hot Penny Stocks to Watch #1: MannKind Corp.
MannKind Corp. is a biopharmaceutical company based in the U.S. The company’s primary focus is on the commercialization of diabetes-related therapeutics. This includes the drugs known as Afrezza and treprostinil, which are both in MannKind’s pipeline. Last month, the company announced that it achieved the final milestone for its agreement with United Therapeutics. With this milestone, MannKind received around $12.5 million in payments from United. The goal of this collaboration is to produce a dry powder formulation of treprostinil. This drug is currently in several clinical trials to see its efficacy in treating pulmonary arterial hypertension.
[Read More] 3 Penny Stocks On Robinhood To Buy Under $3
More recently, MannKind announced that it has entered into an agreement with Vertice Pharma to market and promote Thyquidity, a drug used in the treatment of hypothyroidism. Michael Castagna, CEO of MannKind, states that “we are excited to co-promote Thyquidity with Vertice Pharma. This arrangement allows us to strengthen our relationships with our current customers, expand into pediatric endocrinology and leverage the talent and capabilities of our sales force and reimbursement support systems.”
As a biopharmaceutical company with a lot in the works, MannKind continues attracting attention. With that in mind, will MNKD stock be on your list of the best penny stocks to buy next week or should you avoid it for now?
Hot Penny Stocks to Watch #2: Opko Health Inc.
Opko Health Inc. is another biotherapeutics penny stock with some promising drugs in its pipeline. While the company has several unique deals currently going on, its deal with Pfizer looks like it could begin showing results in the near future. For some context, back in 2014, Opko Health offered Pfizer (PFE Stock Report) a licensing option to be the exclusive distributor of somatrogon around the world. In 2014, Pfizer paid around $295 million for the rights to do so, with the option to pay around $275 million more in the future.
Pfizer recently stated that it plans to submit an offer for regulatory approval to the FDA by the end of the year. This would undoubtedly be big news for both companies and could provide a solid amount of working capital for the future. In addition to this, Opko is working as a part of the covid industry. The company states that at its BioReference Laboratory, it is processing a large quantity of COVID-19 tests. Of course, no one wants COVID cases to rise, but it looks like this is the reality in the short term.
This means that Opko Health could continue to see more business on the covid front. In the past six months, shares of OPK stock have shot up by around 65%. This is quite a sizable gain and should not be ignored. In addition to this, the company recently appointed Dr. Roger Medel to its board of directors. With this expertise, it looks like Opko could have yet another perspective in how to increase the size of its business and the efficacy of the drugs it produces. Opko Health has clearly benefited from increased investor attention in biotech and biopharmaceutical penny stocks. Whether or not it can continue to stay on top in the future remains to be seen. With all of this in mind, investors could consider OPK one to watch before the end of the year.
Hot Penny Stocks to Watch #3: Northwest Biotherapeutics Inc.
Northwest Biotherapeutics Inc. was one of the biggest gainers of the day on December 24th. By midday, shares of NWBO stock were up by as much as 20% to $1.73 per share. While no news came out during the trading day, we did see many biotherapeutic penny stocks rise on Thursday. One of the reasons for this is the fact that 2021 is around the corner. With a new year comes hopes for the potential end of covid. In addition, more vaccines are being distributed every day, meaning that biotech penny stocks are very much in focus. Northwest Biotherapeutics works by producing new ways to treat cancer and other illnesses.
[Read More] The Best Penny Stocks For 2021? 4 Small-Cap Stocks Under $5 To Watch
The company’s flagship drug platform known as DCVax, is being used to activate the immune systems of those who take it. As opposed to traditional cancer drugs, DCVax is used by stimulating patients’ immune systems in order to fight off cancer internally. Of course, it is much more complicated than this, but the basic idea remains the same. Currently, its drug known as DCVax-L could be at the end of a 15-year long clinical trial.
Officially on October 15th, all the necessary data had reportedly been collected, illustrating the desired result. Although COVID has resulted in a slowed-down process for approval, it looks like Northwest Biotherapeutics could be headed in the right direction. If all goes well with this substance moving forward, NWBO could see some obvious benefits.
